When did BioMarin Pharmaceuticals report Q4 2024 earnings?

BioMarin Pharmaceuticals (BMRN) reported Q4 2024 earnings on February 19, 2025 after market close.

What were BioMarin Pharmaceuticals's Q4 2024 revenue and EPS?

BioMarin Pharmaceuticals reported revenue of $738.2M and eps of $0.92 for Q4 2024.

Did BioMarin Pharmaceuticals beat estimates in Q4 2024?

Revenue beat the consensus estimate of $712.3M by $25.9M. EPS beat the consensus estimate of $0.54 by $0.38.

Where can I find BioMarin Pharmaceuticals's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001048477-25-000007) directly on SEC EDGAR. The filing index links above go to sec.gov.

BioMarin Pharmaceuticals BMRN Q4 2024 Annual earnings

Reported February 19, 2025 · After market close

Revenue$738.2MBeat by $25.9M

EPS$0.92Beat by $0.38

Revenue estimate$712.3M

EPS estimate$0.54

Next report

Aug 3, 2026 (In 4 days)

Revenue estimate$932.0M

EPS estimate$0.96

Financials

Q4 2024

Income statement

See full

Revenue$747.3M+15.6%

Gross profit$611.2M+20.2%

Operating income$161.4M+492%

Net income$124.9M+513%

EPS (diluted)$0.65+550%

Balance sheet

See full

Cash & equivalents$942.8M+24.9%

Total debt$38.8M-92.8%

Total equity$5.7B+14.3%

Total assets$7.0B+2.2%

Cash flow

See full

Operating cash flow$185.6M+575%

CapEx$19.5M-32.5%

Free cash flow$166.1M—

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$12.53B-31.0%

Enterprise value$11.62B-35.2%

P/E29.3×-79.0×

P/S4.4×-3.1×

Profitability

See full

Gross margin79.7%+1.7pp

Operating margin17%+9.3pp

Net margin15%+8.0pp

FCF margin17.1%—

Returns & leverage

See full

Return on equity8%+4.5pp

Debt / equity0×-0.1×

Current ratio5.3×+2.8×

Segments

By product

See full

VOXZOGO$208.5M+43.1%

VIMIZIM$191.1M+8.8%

NAGLAZYME$110.0M+12.0%

PALYNZIQ$100.4M+14.3%

BRINEURA$47.7M+9.3%

By segment

See full

Reportable Segment$747.3M+23.6%

Versus estimates

Revenue

Q1 2026$766.0MBeat by $13.5M Q4 2025$874.6MBeat by $40.8M Q3 2025$776.1MMiss by $47.3M Q2 2025$825.4MBeat by $63.5M Q1 2025$745.1MMiss by $17.3M

Q4 2024$738.2MBeat by $25.9M

Diluted EPS

Q1 2026$0.55Miss by $0.39 Q4 2025-$0.24Miss by $0.41 Q3 2025$0.12Beat by $0.27 Q2 2025$1.44Beat by $0.58 Q1 2025$1.13Beat by $0.19

Q4 2024$0.92Beat by $0.38

Ask the moment BioMarin Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did BioMarin Pharmaceuticals report Q4 2024 earnings?: BioMarin Pharmaceuticals (BMRN) reported Q4 2024 earnings on February 19, 2025 after market close.
What were BioMarin Pharmaceuticals's Q4 2024 revenue and EPS?: BioMarin Pharmaceuticals reported revenue of $738.2M and eps of $0.92 for Q4 2024.
Did BioMarin Pharmaceuticals beat estimates in Q4 2024?: Revenue beat the consensus estimate of $712.3M by $25.9M. EPS beat the consensus estimate of $0.54 by $0.38.
Where can I find BioMarin Pharmaceuticals's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001048477-25-000007) directly on SEC EDGAR. The filing index links above go to sec.gov.